Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram for Prevention of Interferon-Associated Depression in HCV
NCT00136318Phase 3Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2004
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Escitalopram with Placebo (2 arms). Primary endpoint: Incidence of depression defined as a Montgomery Asberg Depression Scale Score (MADRS) of 13 or higher up to 48 weeks. Started Jan 2004; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00136318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00136318.